SCB
ALNY icon

Saudi Central Bank’s Alnylam Pharmaceuticals ALNY Stock Holding History

Saudi Central Bank’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.61M Buy
+4,876
New +$1.66M 0.03% 236
2025
Q2 		– Sell
-51
Closed -$13.8K – 80
2025
Q1 		$13.8K Buy
+51
New +$13.1K 0.07% 249

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Saudi Central Bank's ALNY Position: Q1 2026 in Review

Saudi Central Bank opened a new position in Alnylam Pharmaceuticals (ALNY) in Q1 2026: 4,876 shares worth $1.61M. The stake represents 0.03% of the portfolio and ranks #236 among its holdings. This is a return to the name: Saudi Central Bank previously reported a position in ALNY as recently as Q1 2025.

Saudi Central Bank first reported a position in ALNY in Q1 2025 and has held it in 2 quarters since. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Saudi Central Bank held 4,876 shares of Alnylam Pharmaceuticals worth $1.61M as of Q1 2026.
  • Alnylam Pharmaceuticals was a new Saudi Central Bank position in Q1 2026.
  • Alnylam Pharmaceuticals made up 0.03% of Saudi Central Bank's portfolio in Q1 2026, its #236 holding.
  • Saudi Central Bank first reported a position in Alnylam Pharmaceuticals in Q1 2025 and has held it in 2 quarters since.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Saudi Central Bank's 13F filing for Q1 2026, filed 15 May 2026.